Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Another scam artist with ties to stock market media group and KW.
What do most people think Kenny Boy does all day? What very little being done is all done by outside vendors. What does Kenny and his boys Carlos and Gerald do all day everyday.
Seems obvious that this pretend biotech PMCB is just a way of legally stealing money from naive investors and enriching a group of Shady old men.
Going on EIGHT YEARS of accomplishing ZERO!!!
IMHO !!
And yet those trials are not recognized by the FDA because they were not done under proper controls so what real evidence do we have that CIAB does anything.
No Interest from any other Biotech.
No Interest from any Financing Organization.
Just a couple old guys sucking every penny raised by selling shares at 67% discounts into their wallets.
7 years of false promises and lies.
IMHO! Naturally
Every treatment ever involved in a clinical trial has had GREAT animal pre-clinical results. If they didn't no IND would ever have been issued. Very few ever repeat the results in humans though as proven by the small percentage of approval (9.6%)
One shot to get what right? Many companies have their IND's delayed by the FDA for needing more information or further tests. This "we only have one shot to get this right" narrative by Shady Kenny is just his way of delaying. If they were so close to IND why have there been no further interactions with the FDA? Biotechs can request as many interactions with the FDA as they need. Its been almost 20 months since their pre-ind meeting and still no timeline. Who is doing all of the necessary paperwork and compiling all of the data they will need? They have no regulatory people on the payroll and they have no CRO. Just keep milking the months away KW and keep rewarding yourself with more and more cash as you enjoy retirement because even your own PR people admit that PMCB does nothing it is all farmed out to contractors. Yet Kenny boy is too busy to have a shareholder update or even a press release. SCAM! IMHO of course!!
Until PMCB actually starts a clinical trial they are a SCAM. Who cares about Eurofins (they are a vendor they don't do background checks on customers. And the Doctors? The doctors are paid consultants that also consult for numerous other companies as well as having their own full time jobs. A company that hypes a treatment going on 8 years and provides no timelines or pre-clinical or clinical data other then 20+ year old data not recognized by the FDA and has no CRO or funding to conduct trials or even the preliminary work for trials will always be a SCAM until they prove they are not. Anyone who tells you their is partnerships or funding is flat out lying as any of this activity would be filed in an 8k. Buyer beware this con-job has been going on for a LONG TIME. IMHO!
Here is an example of the many lies Shady Kenny has told. How many more would you like.
SILVER SPRING, Md., April 10, 2014 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, reported today that it has signed a Master Services Agreement with ViruSure GmbH, located in Vienna, Austria, to develop and maintain Master, Working and End of Production Cell Banks. These cell banks are necessary steps in the production of the cells to be encapsulated using the Cell-in-a-Box(R) technology for PharmaCyte Biotech’s Phase 2b clinical trials in advanced, inoperable pancreatic cancer to be conducted in Australia.
“ViruSure has previous experience in handling the exact cell line that will be used in our Phase 2b clinical trials, which was a major factor in PharmaCyte Biotech selecting ViruSure for this important step in our preparations for these trials,” said Kenneth L. Waggoner, CEO and President of PharmaCyte Biotech. “This decision was further supported by our on-site inspection of the ViruSure facilities and the excellent historical relationships between ViruSure’s key personnel with our partners at Austrianova. ViruSure has years of experience in producing and maintaining cell banks and is an industry leader in this arena.”
“We are delighted to be partnering with PharmaCyte Biotech on such an important project and in helping to bring this much needed therapy for such a devastating disease as pancreatic cancer to the clinic,” stated Andy Bailey, CEO and co-founder of ViruSure.
The cells that will make up the Master, Working and End of Production Cell Banks will be those that convert the anticancer drug ifosfamide into its cancer-killing form. These therapeutic cells will be shipped to ViruSure for propagation. First a Master Cell Bank will be established where aliquots of cells will be stored frozen. Cells from the Master Cell Bank will be propagated to make up the large number of cells that will comprise the Working Cell Bank. Ultimately, cells from the Working Cell Bank will be encapsulated using the Cell-in-a-Box(R) live cell encapsulation technology. An End of Production Cell Bank will then be made from the final product for quality control purposes. The encapsulated cell product, together with ifosfamide, forms PharmaCyte Biotech’s treatment for pancreatic cancer.
Its LOL funny how PMCB spent 5 years talking about conducting a clinical trial SOON only to have a pre-clinical meeting with the FDA which they could have had at anytime during those five years. Now PMCB has spent almost 2 years talking about a filing an IND. Meanwhile KW and his little band of thieves have collected tens of millions$$ in pay and stock and still there are those who try to convince new investors that this is a real company. PMCB is a stock selling hoax with no financial means to even file an IND never mind starting a clinical trial. Always just enough money on hand to pay the crooks though. IMHO Nat !!
My guess is PMCB will prolong this alleged "IND/Trial" angle as long as they can continue to sell shares and pay crooked management millions every year. There is not one single piece of evidence that any company is interested in partnering or buying out PMCB's two man band in a rented closet. IMHO of coarse !!
PMCB is a Giant Red Flag not just a company with a few red flags.
7 Years of Hyping a clinical trial "soon".
2 Years of claiming an Ind "soon" yet no timeline to speak of as if PMCB is the first company ever to file an Ind.
1.1 BILLION shares outstanding.
Company sells tens of millions of shares every qtr at 66% discounts.
Almost every penny of these share dumps is used to pay management and their "consultants"
Very little cash on hand not even enough to file an Ind never mind paying for a trial that will cost at least $15 million.
No CRO to run this alleged clinical trial.
No company updates to shareholders via PR or CC.
Company is run by a 70 year old lawyer and a 80 year old retired Dr with no actually facility just a closet rented in California.
Do some real DD read the companies own PR's on their website that legally have to remain there for years. Search for Nuvilex and Efood Safety (Their former names (another RED FLAG) read their pathetic financial statements and outrageous salaries given to non-producing management year after year.
Realize that most positive posts are written by 10-15 year owners of this stock who pretend to know about biotech companies yet invested in a company that tracked produce. Then became a "natural cancer cure hangover cure company'. Then spent a few pennies to buy a 25 year old technology that No One wanted and pooooof became a biotech.
IMHO naturally !!!!!!!
When you invest in a do nothing but sell shares and pay Shady Management company you shouldn't really expect anything more then what Kenny and PMCB gives you. Its not like this company doesn't have a long history of doing nothing but releasing hyped up PR's and selling hundreds of millions of shares at 66% discounts. Do yourself a favor when you research PMCP also search for Nuvilex and e food safety. You will be glad you did. IMHO of course!!
Sure! LOL A company that is going to make everyone rich is selling shares at a 66% discount(2.3 cents) just so they have enough money to pay its do nothing Shady management. If this 10K doesn't prove PMCB is nothing but a stock selling scam its only because to some total blind people nothing will.
Although the FDA may accept data from clinical trials conducted outside the U.S., acceptance of this data is subject to certain conditions
imposed by the FDA. There is a risk that the FDA may not accept the data from the two previous trials. In that case, we may be required to
conduct a Phase 1 or a Phase 1/2b clinical trial rather than the planned Phase 2b clinical trial in LAPC. This may result in additional costs to
us and resultant delays in the regulatory review process and any future commercialization and marketing, if regulatory approval is obtained.
It is not known whether the FDA would be likely to reject the use of such clinical data due to the significant time that has elapsed since the
earlier clinical trials were conducted or because the clinical trial material for our proposed Phase 2b clinical trial is different from that used
in the earlier clinical trials because of cloning the cells used in the earlier trials and certain other modifications and improvements that have
been made to the Cell-in-a-Box
®
technology since the time of the earlier trials.
Kenneth L.Waggoner, J.D. Total Compensation FY 2018 $1,004,360
From May 1, 2018 through July 20, 2018, the Company sold 66,239,316 shares of common stock using the Second S-3 structured as a
Block Trade. The issuance of these shares resulted in gross proceeds to the Company of approximately $1,500,000. Pursuant to the Aeon
Agreement, the Company is required to pay Aeon a fee of 7%, $105,000 and provide warrant coverage of 5% of the number of shares of
commons stock sold in the Block Trade with a five-year term of approximately 3.3 million warrant shares.
That is .023 cents per share.
It is very comical to watch. I think PMCB has been foolishly linked to every Biotech in the world at one time or another by someone on this board. Yet here we are a stock selling scam of a company that has owned CIAB technology for 8 years and all they have accomplished is having a vendor create a master cell bank. Meanwhile Shady Kenny has sucked more money out of this company then it would have taken to conduct two clinical trials. But don't worry "we are there" LOL !!!!
As always IMHO.
What schedule is that? The same one PMCB has been on for 7 years? Soon. LOL There is no schedule for a company that is only in business to sell shares and pay Millions to its Shady management. IMHO!!!!!
At some point most will learn that all of these so called delays are on purpose. Shady Kenny and his pals are all well past retirement age and are just looking to suck as much money out of naive penny stock investors as they can. Partnerships and buyouts? LOL the technology has been out there for 20 years for all to see and real Biotech's snatch up real technology for big money every week and it should be as obvious as being punched in the face that no Biotech has any interest in the share selling scam that is PMCB. Your hero KW is doing nothing more then enjoying a non-stop vacation with his new bride for years now.
Yet another lie. Pre-Ind meeting was announced by Shady Kenny on 1/4/17 and the meeting was held on 1/17/17. Imagine its been 539 days since their meeting and what has happened since? They have a cell bank which they also claimed to have had 6 years ago. But Kenny and his buds are a lot richer.
http://pharmacyte.com/pharmacyte-biotech-announces-pre-ind-meeting-date-fda/
Really? Celgene isn't interested in a company that has stumbling and bumbling around for 8 years pretending that they are a real biotech all while only being interested in selling shares and paying Shady Kenny and his crooked friends? Surprising!
Since the 6/6/18 hype SMMG article the volume is around 60 million more shares then average. Strange how PMCB sold 62.4 million shares at .028 last qtr to Kenny's buddies. First the pump then .....
Looks like the no news news releases the past few weeks were only so Shady Kenny's friends could unload the 3 cent shares the bought last Qtr for a 200% profit. PMCB going on 7 years of empty promises of clinical trials while only making management and managements friends rich. IMHHO!!!!!
Congrats to the people that flipped the 62.4 million shares they purchased from PMCB for .028 earlier this year into a sweet profit over the past two weeks.
What a clown show. PMCB spends millions over the past 6 years on fake PR's from stock market media group and other paid for penny stock promoters. Spends millions on do nothing management. Spends millions keeping the Austrianova clowns in business. And what has been accompliahed in those 6 years? They had someone grow a cell bank. 70+ year old KW and 80 year old Crabtree laughing all the way to retirement.
LOL. The "Big Pharma" "Market Makers" conspiracy is back. Meanwhile Big Pharma spends Billions every year partnering with or paying huge premium buyouts for clinical stage biotech's it seems every week. PMCB has a $50 million market cap if any real Biotech thought they had anything worth owning they would have bought them out or partnered with them eagerly. But by all means keep the tin foil hats on and keep waiting for Shady Kenny and his band of thieves to produce something.
This looks like a date also.
PharmaCyte Biotech on Schedule for 2016 Cancer Clinical Trial in Pancreatic Cancer
25 FEB 16
SILVER SPRING, Md., Feb. 24, 2016 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, issued a further update on its upcoming clinical trial in pancreatic cancer. In this update, PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, clarifies statements made earlier this week that reportedly confused numerous shareholders and potential investors.
“Last Monday I tried to address certain issues that shareholders and potential investors have raised repeatedly about our upcoming clinical trial and provide an update on our efforts to complete the process of preparing the Investigational New Drug application (IND) that PharmaCyte must submit to the FDA to start our clinical trial in pancreatic cancer. Given the number of telephone calls and emails the Company has received since that update was published, it has become apparent that the update caused confusion and raised issues of concern that were never intended.
“When it was stated on Monday that the expected ‘start date’ for PharmaCyte’s clinical trial in pancreatic cancer remains difficult to announce with certainty, we were not implying that we aren’t still on schedule to get into the clinic in 2016 or that we don’t have any idea when we will be in the clinic. We plan to be in the clinic well before the end of this year. It was simply a statement that intended to refrain from announcing a specific date or time period for starting the trial because much of what is left to complete is out of our control.
“PharmaCyte is involved in a well-planned, detailed and methodical process to insure that every aspect of the IND is correct before we submit the IND to the FDA. As the “Sponsor” of the IND, it is our responsibility to insure that the Chemistry, Manufacturing and Controls (CMC) section of the IND is complete and accurate in every respect. We are working with Translational Drug Development (TD2), Chamow & Associates (Chamow) and Austrianova in completing everything that is required. It is a process that began last year and is well underway.
“TD2 is fully engaged and working diligently in all aspects of preparing for the clinical trial. With respect to developing the CMC information, the process is complicated, labor intensive and highly technical. But with TD2 taking the lead, working in concert with Chamow and Austrianova, I am very confident that our schedule is on track.”
Really because these look like a date.
16 MAR 15
SILVER SPRING, Md., March 16, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R), today provided shareholders with an update on developments on progress in its cancer and diabetes programs and at the corporate level.
Kenneth L. Waggoner, Chief Executive Officer of PharmaCyte Biotech, stated, “Given all of the developments that have occurred since our last update, we believe it is an appropriate time to update our shareholders on developments and to highlight and briefly summarize what is in store for PharmaCyte Biotech in the coming days. Before doing so, however, we would like to address two issues that reportedly are of significant concern to a number of our shareholders. The first has to do with whether a reverse stock split is imminent. The second is whether we have access to capital to move forward with our clinical trials. PharmaCyte Biotech has no current plans to effectuate a reverse stock split. In addition, our cash position remains strong and our ability to raise capital continues to be very favorable.”
“As to the update, we remain focused on bringing our diverse platform technology to market and firmly believe our novel Cell-in-a-Box-based treatment will become a household name in the future. Our priority is and always has been to maximize shareholder value, and we are working diligently to reach that objective,” added Mr. Waggoner.
Progress in the Cancer Program
PharmaCyte Biotech’s treatment (Cell-in-a-Box(R) plus low-doses of ifosfamide) for advanced, inoperable pancreatic cancer was granted the Orphan Drug designation by the U.S. Food and Drug Administration (FDA) in late December of 2014.
On the basis of very positive results from our first preclinical study (4 groups of tumor bearing mice) that was conducted by Translational Drug Development (TD2) in the U.S. to determine the ability of the Cell-in-a-Box(R) plus low-doses of ifosfamide combination to delay the accumulation of malignant ascites fluid produced by abdominal cancers, an expanded study (12 groups of mice) is currently being conducted by TD2. This study is designed to elucidate parameters that will be needed for a future clinical trial that may result in the only treatment that can slow down the accumulation of malignant ascites fluid. It is expected that the study will be completed in the next 2 months. The target date for the initiation of the Phase 1 clinical trial in the U.S. is the third quarter of 2015.
Preparations for the Phase 2b clinical trial in patients with advanced, inoperable pancreatic cancer are ongoing. Major documents, including the Investigators Brochure and a clinical protocol (a recipe for conducting the clinical trial) are in preparation, with the assistance of Clinical Network Services (CNS) – one of Australia’s leading Clinical Research Organizations. The target date for the initiation of the Phase 2b clinical trial in Australia is the third quarter of 2015.
We initially reported that we expected to begin our Phase 2b clinical trial in the first quarter of 2015; however, we are awaiting the Good Manufacturing Practices (GMP) regulatory approval process that our partner, Austrianova, is currently involved with in order to get the GMP-compliant facility at the Thai Science Park in Bangkok, Thailand, approved to produce Cell-in-a-Box(R) capsules for human clinical trials. Austrianova believes the process will now be completed in the third quarter of 2015.
Progress is ongoing at the University of Northern Colorado in an attempt to identify a cell line that can be encapsulated using the Cell-in-a-Box(R) technology, which, in turn, can be used together with cannabinoid or cannabinoid-like prodrugs as a treatment for deadly cancers – such as brain and pancreatic cancer.
Interview? Its a paid for promotion by PMCB to Stock Market Media Group. Shady Kenny is to busy to have an investor update CC but has plenty of time to write question for his paid for puppet KK to interview him. LOL Such a sleazy company.
Stock Market Media Group back releasing hype PR's. This company will never change. A radio style interview with a script written by KW and conducted by a paid associate. LOL!!
Not if that's all they do Bra.
Selling shares at 60% discount. That is all this company does is sell shares and issue PR's. 6 years of owning a technology and not one data presentation. Just lie after lie. Clinical trials starting in 2013-2014-2015-2016-2017. Now maybe IND in 2018. Meanwhile almost every penny raised selling shares at 60% discounts goes directly in the pocket of shady management.
The issue here is that many have become so numb to the incompetence and lack of any real achievements in the past 5+ years that any PR makes them think something major happened. Eurofins produced a master cell bank and tested it. WOW the biotech world is in awe!
Its a miracle that someone can grow a cell line and test it? There isn't a real biotech in the world that would consider that PR worthy.
What news is that? PMCB cells passed some tests done by a vendor. What scientific publication would release that? Maybe if PMCB released real information like pre-clinical data or "Actual Clinical Data" someone would but no medical or scientific publication is going to release Kenny's bogus PR's as real news.
Giving more money to Austrianova. What a surprise! LOL
A new Section 6.e. shall be added to the Third Addendum to read as follows: Licensee shall pay an aggregate total amount
of Nine Hundred Thousand Dollars US (US$900,000.00) to Austrianova ratably over a nine (9) month period in the amount
of two (2) Fifty Thousand Dollars US (US$50,000.00) payments each month during the nine (9) month period on the days
of the month to be agreed upon between the parties, with a cure period of twenty (20) calendar days after receipt by
Licensee of written notice from Licensor that Licensee has failed to pay timely a monthly payment of One Hundred
Thousand Dollars US (US$100,000) required by this Section 6.e.
Because he is a BS artist. Has anything Shady Kenny said in the past 6 years ever happen?
The P2B in Australia? Nope
The pre-clinical data on ascites? Nope
The Pre-clinical data on Diabetes? Nope
Partnerships or funding from all the NDA's signed? Nope
The P3 trial that TD2 would run? Nope
The clinical trials soon in 2013-2014-2015-2016-2017? Nope
With every silly PR released that they completed a test it just shows how dishonest this company is and always has been. How could they have started a clinical trial in 2013-14-15-16-17 when they had none of these tests completed?
Because its not about a clinical trial its about promoting a clinical trial so they can get paid year after year. Issue PR's sell shares pay themselves and repeat.
Maybe someone who continues to claim this company is legit can explain to any potential new investor how PMCB plans on raising 15-20 million dollars to pay for IND,trial prep and trial execution. All I see is a company that continues to sell just enough shares at 60% discounts to pay its crooked incompetent management every Qtr.
Many buy in on the words of some that have been here for 10-15 years chirping about the "Great Technology and dreams of making millions". Their posts are the same over and over "Kaboom Coming" "Great buying opportunity at these crazy low prices" "Bid Pharma is paying MM's because they are scared of PMCB" Blah Blah Blah. Meanwhile the crooks running this stock selling company laugh their way into a wealthy retirement.
Sometimes some take longer then others to realize that PMCB stock is for trading not for holding. All one has to do is look at the history of a company that is all about PR's and selling shares and accomplishing absolutely NOTHING.